To the content


The research team at AOP Health covers all essential aspects of product development, starting with preclinical research and extending to toxicology, pharmaceutical development, clinical development, regulatory affairs, quality management, pharmacovigilance, and project management. Experts in the individual specialties work as project managers in close cooperation with each other and with external service providers and partners, in order to implement the ambitious research projects of the organization.

Indication Status Phase I Phase II Phase III Registration Marketed
Polycythemia Vera Phase IV
Essential Thrombocythemia Phase III
Myelofibrosis Phase II
CML Endure Phase III
Indication Status Phase I Phase II Phase III Registration Marketed
Supraventricular tachycardia Under registration in USA
Supraventricular tachycardia (septic shock patients) Phase IV in EU
Supraventricular tachycardia (pediatric patients) Phase III in EU
Ventricular tachycardia Phase III in EU
Landi POAF Phase III in EU, CAN & USA
Indication Status Phase I Phase II Phase III Registration Marketed
Pulmonary Arterial Hypertension Phase IV in EU
Pulmonary Arterial Hypertension Phase III in EU
Indication Pre- Clinical Phase I Phase II Phase III Registration Marketed
Acute Myeloid Leukemia and Myelodysplastic Syndrome (study start 2023)

Significance of the phases

The tolerance and safety of the drug are tested in a phase-I study. Those conducting the study investigate how the active substance is absorbed by the body and draw preliminary conclusions about the appropriate dosage. The trial is conducted in a small group of healthy probands or severely ill patients.

The aim of this study phase is to obtain evidence of the efficacy of the tested drug and to confirm the therapy concept. Based on the results of the first study phase, another point of focus in phase II is the determination of the optimal dose, which is then used in phase III. The investigations are conducted in a precisely defined and limited group of patients.

Based on large-scale trials, in this phase the investigator obtains decisive data for the approval of the drug. The study conditions should be such that they largely concur with the subsequent therapy situation. The study includes a large number of patients who are then divided into randomized comparative groups and receive the new active substance or an already approved drug or a placebo. This permits a direct comparison of the employed substances.

Phase IV trials consist of further clinical studies performed with the already approved drug. By treating a much larger group of patients, in this phase it is possible to identify and register rare side effects as well as interactions with other drugs and optimize the use in the approved indication.

Dr. Martin Unger

A trustful relationship with investigators and study staff in every single center, quick communication, competence synergies – all of these aspects are of vital importance for the success of our studies.

Dr. Christoph Klade

AOP Health has successfully developed a number of innovative treatment options in recent years. To arrive at these, our thinking is guided above all by patient needs.

To the main navigation